Golimumab (Simponi) IV in combination with methotrexate (MTX) for the treatment of adult patients with moderately to severely active rheumatoid arthritis
Rheumatoid arthritis (RA) is a chronic, inflammatory disease characterized by joint swelling, joint tenderness, and destruction of synovial joints, leading to severe disability and premature mortality. Disease prevalence in Canada is about 1% (0.9% in 2010), and it is expected to increase to 1.3% by...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2015, 2015
|
| Series: | Common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Rheumatoid arthritis (RA) is a chronic, inflammatory disease characterized by joint swelling, joint tenderness, and destruction of synovial joints, leading to severe disability and premature mortality. Disease prevalence in Canada is about 1% (0.9% in 2010), and it is expected to increase to 1.3% by 2040. Treatment guidelines for RA emphasize the use of non-drug interventions, which include exercise therapy, electro-physical modalities, orthoses and assistive devices, and self-management interventions (including education), in addition to pharmacological therapy. Non-pharmacological care affords symptomatic relief without altering the course of disease progression. The pharmacological therapy of RA aims to achieve remission and, if that is not possible, to minimize disease activity while controlling symptoms, halting joint damage, preventing disability, and improving quality of life. The objective of this report is to evaluate the beneficial and harmful effects of IV golimumab (Simponi IV) at recommended doses in combination with methotrexate for the treatment of adult patients with moderately to severely active RA. Traditional synthetic, disease-modifying antirheumatic drugs (DMARDs) have been shown to alter the clinical course of RA and slow or halt radiographic progression when used early and aggressively in the treatment of RA. Methotrexate is the preferred DMARD with respect to efficacy and safety, and is recommended as the first-line DMARD treatment in patients with RA unless contraindicated or not tolerated. Nonsteroidal anti-inflammatory drugs (NSAIDs) and/or glucocorticoids (in the lowest effective dose possible) can be added to the initial treatment with DMARD as a bridge therapy while waiting for DMARD to take effect, to manage flares, or for symptom control if no other options exist. It is recommended that patients with an inadequate response to the target dose of at least two DMARDs in mono- or combination therapy after three months be considered for biologic therapies, including currently available subcutaneous (SC) golimumab that targets specific mechanisms of inflammation. |
|---|---|
| Physical Description: | 1 online resource |